RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of DXCM
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

DexCom stock price ended at $138.70 on Thursday, after losing 0.559%.
(Updated on Mar 28, 2024)

Buy or Hold candidate since Mar 01, 2024 Gain 13.93% PDF

The DexCom stock price fell by -0.559% on the last day (Thursday, 28th Mar 2024) from $139.48 to $138.70. It has now fallen 3 days in a row. During the last trading day the stock fluctuated 1.65% from a day low at $138.52 to a day high of $140.80. The price has fallen in 6 of the last 10 days but is still up by 7.1% over the past 2 weeks. Volume has increased on the last day by 458 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 2 million shares were bought and sold for approximately $343.04 million.

The stock lies in the upper part of a wide and weak rising trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break-up at the top trend line at $140.56 will firstly indicate a stronger rate of rising. Given the current short-term trend, the stock is expected to rise 7.21% during the next 3 months and, with a 90% probability hold a price between $125.94 and $150.69 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

DXCM Signals & Forecast

There are mixed signals in the stock today. A sell signal was issued from a pivot top point on Monday, March 25, 2024, and so far it has fallen -1.00%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely. The DexCom stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $136.76 and $126.22. A breakdown below any of these levels will issue sell signals.

Support, Risk & Stop-loss for DexCom stock

DexCom finds support from accumulated volume at $133.72 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $2.29 between high and low, or 1.65%. For the last week, the stock has had daily average volatility of 2.96%.

Our recommended stop-loss: $134.23 (-3.22%) (This stock has medium daily movements and this gives medium risk. There is a sell signal from a pivot top found 3 days ago.)

Trading Expectations (DXCM) For The Upcoming Trading Day Of Monday 1st

For the upcoming trading day on Monday, 1st we expect DexCom to open at $139.34, and during the day (based on 14 day Average True Range), to move between $134.57 and $142.83, which gives a possible trading interval of +/-$4.13 (+/-2.98%) up or down from last closing price. If DexCom takes out the full calculated possible swing range there will be an estimated 5.96% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $139.48 (0.56%) than the support at $133.72 (3.59%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is DexCom stock A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for DexCom stock to perform well in the short-term.

Current score: 2.535 Buy Candidate Unchanged

Predicted Opening Price for DexCom of Monday, April 1, 2024

Fair opening price April 1, 2024 Current price
$139.34 ( 0.460%) $138.70

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for DXCM

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 141.62 2.11 %
R2 140.75 1.48 %
R1 140.21 1.09 %
Current price: 138.70
Support S1 138.47 -0.169 %
S2 137.93 -0.558 %
S3 137.05 -1.19 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 140.10 1.01 %
R2 139.93 0.89 %
R1 139.48 0.562 %
Current price 138.70
Support S1 133.72 -3.59%
S2 120.47 -13.14%
S3 116.26 -16.18%

FAQ

What is the symbol for DexCom Stock and on which exchange is it traded?
The symbol for DexCom is DXCM and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell DexCom Stock?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for DexCom stock to perform well in the short-term.

How to buy DexCom Stock?
DexCom Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy DexCom Stock.

What's the current price of DexCom Stock?
As of the end of day on the 2024-03-28, the price of an DexCom (DXCM) share was $138.70.

What is the 52-week high and low for DexCom Stock?
The 52-week high for DexCom Stock is $142.00 and the 52-week low is $74.75.

What is the market capitalization of DexCom Stock?
As of the 2024-03-28, the market capitalization of DexCom is 53.772B.

When is the next earnings date for DexCom?
The upcoming earnings date for DexCom is Apr 25, 2024.
Click to get the best stock tips daily for free!

About DexCom

DexCom DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to i... DXCM Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT